{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:09:31Z","timestamp":1791223771786,"version":"4.1.0"},"reference-count":12,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2010,4,12]],"date-time":"2010-04-12T00:00:00Z","timestamp":1271030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2010,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Objective:\u2002<\/jats:bold> Myelodysplastic syndrome (MDS) treatment can initially worsen patients\u2019 clinical condition and they may discontinue therapy before achieving benefit. We present previously unpublished data from two large phase III trials describing common adverse events (AEs) associated with azacitidine and methods to manage them.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> In the Cancer and Leukemia Group B (CALGB) 9221 study, patients with any French\u2010American\u2010British (FAB) subtype of MDS were randomized to azacitidine or best supportive care (BSC). After 56\u2003d, patients randomized to BSC with disease progression could cross over to receive azacitidine. In the AZA\u2010001 study, patients with higher\u2010risk MDS (FAB\u2010defined refractory anemia with excess blasts (RAEB), RAEB in transformation, or chronic myelomonocitic leukaemia and IPSS int\u20102 or high) were randomized to azacitidine or to conventional care regimens (CCR), which included low\u2010dose ara\u2010C, BSC, or intensive chemotherapy. In both studies, azacitidine dose was 75\u2003mg\/m<jats:sup>2<\/jats:sup>\/d SC for 7\u2003d every 28\u2003d. AEs were graded per National Cancer Institute\u2019s Common Toxicity Criteria version 2.0 (AZA\u2010001) or CALGB Expanded CTC (CALGB 9221).<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> In safety\u2010evaluable patients in AZA\u2010001 (<jats:italic>N\u2003<\/jats:italic>=\u2003175) or CALGB 9221 (<jats:italic>N\u2003<\/jats:italic>=\u2003150), the most common AEs with azacitidine included hematologic (eg, cytopenias) and non\u2010hematologic administration\u2010related events (eg, injection\u2010site reactions and gastrointestinal disorders). Most AEs were transient and resolved during ongoing therapy (&gt;\u200383%). Hematologic AEs, most frequently observed during early treatment cycles, decreased during subsequent cycles and were usually managed with dosing delays (23\u201329%). Gastrointestinal symptoms were primarily managed with anti\u2010emetics and laxatives.<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> Hematologic and non\u2010hematologic AEs with azacitidine decreased in frequency as treatment continued. Awareness of the onset, duration and management of AEs can facilitate treatment, permitting patients to continue therapy for maximum benefit.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2010.01456.x","type":"journal-article","created":{"date-parts":[[2010,4,12]],"date-time":"2010-04-12T09:45:55Z","timestamp":1271065555000},"page":"130-138","source":"Crossref","is-referenced-by-count":111,"title":["Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*"],"prefix":"10.1111","volume":"85","author":[{"given":"Valeria","family":"Santini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam J.","family":"Mufti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hellstr\u00f6m\u2010Lindberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis R.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"List","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Backstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Beach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,7,14]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn349"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.2079"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.04.117"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.04.044"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70003-8"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.4346"},{"key":"e_1_2_6_8_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.227.227","article-title":"The effects of continued azacitidine (AZA) treatment cycles on response in higher\u2010risk patients (Pts) with myelodysplastic syndromes (MDS)","volume":"112","author":"Silverman LR","year":"2008","journal-title":"Blood"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70048-8"},{"key":"e_1_2_6_10_2","first-page":"1286","article-title":"Evidence\u2010 and consensus\u2010based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology","volume":"87","author":"Alessandrino EP","year":"2002","journal-title":"Haematologica"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.03907.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.1058"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.26.15_suppl.7006"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2010.01456.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2010.01456.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T01:53:36Z","timestamp":1698630816000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2010.01456.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,14]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["10.1111\/j.1600-0609.2010.01456.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2010.01456.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,14]]}}}